NASDAQ:MLNT - Melinta Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.25 +0.95 (+17.92 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$6.25
Today's Range$5.35 - $6.55
52-Week Range$5.20 - $24.25
Volume1.41 million shs
Average Volume224,913 shs
Market Capitalization$195.27 million
P/E Ratio-0.29
Dividend YieldN/A
Beta1.38

About Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics logoMelinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut.

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MLNT
CUSIP15130J10
Phone312-767-0291

Debt

Debt-to-Equity Ratio0.53
Current Ratio1.48
Quick Ratio1.20

Price-To-Earnings

Trailing P/E Ratio-0.29
Forward P/E Ratio-1.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.86 million
Price / Sales5.79
Cash FlowN/A
Price / CashN/A
Book Value$6.37 per share
Price / Book0.98

Profitability

EPS (Most Recent Fiscal Year)($21.86)
Net Income$-58,910,000.00
Net Margins-327.21%
Return on Equity-49.88%
Return on Assets-28.93%

Miscellaneous

Employees300
Outstanding Shares31,370,000

Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics (NASDAQ:MLNT) announced its earnings results on Tuesday, March, 13th. The biotechnology company reported ($1.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.89. The biotechnology company had revenue of $4.23 million for the quarter, compared to analyst estimates of $3.28 million. Melinta Therapeutics had a negative return on equity of 49.88% and a negative net margin of 327.21%. View Melinta Therapeutics' Earnings History.

When is Melinta Therapeutics' next earnings date?

Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Melinta Therapeutics.

What price target have analysts set for MLNT?

7 Wall Street analysts have issued 1-year price objectives for Melinta Therapeutics' stock. Their predictions range from $2.00 to $8.00. On average, they anticipate Melinta Therapeutics' stock price to reach $4.20 in the next year. View Analyst Ratings for Melinta Therapeutics.

Who are some of Melinta Therapeutics' key competitors?

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the folowing people:
  • Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 50)
  • Mr. Daniel Mark Wechsler, Pres & CEO (Age 50)
  • Dr. Thomas A. Steitz Ph.D., Co-Founder
  • Dr. Peter B. Moore Ph.D., Co-Founder
  • Dr. William L. Jorgensen Ph.D., Co-Founder

Has Melinta Therapeutics been receiving favorable news coverage?

News coverage about MLNT stock has been trending positive on Saturday, according to Accern. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Melinta Therapeutics earned a news sentiment score of 0.36 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.59 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Melinta Therapeutics' major shareholders?

Melinta Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vatera Holdings LLC (27.86%), BlackRock Inc. (2.74%), Dimensional Fund Advisors LP (1.52%), Millennium Management LLC (1.42%), Sphera Funds Management LTD. (0.78%) and Northern Trust Corp (0.53%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.

Which institutional investors are selling Melinta Therapeutics stock?

MLNT stock was sold by a variety of institutional investors in the last quarter, including A.R.T. Advisors LLC and Gabelli Funds LLC. View Insider Buying and Selling for Melinta Therapeutics.

Which institutional investors are buying Melinta Therapeutics stock?

MLNT stock was acquired by a variety of institutional investors in the last quarter, including Vatera Holdings LLC, BlackRock Inc., Millennium Management LLC, Stifel Financial Corp, Eversept Partners LLC, Northern Trust Corp, Dimensional Fund Advisors LP and Sphera Funds Management LTD.. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.

How do I buy shares of Melinta Therapeutics?

Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Melinta Therapeutics' stock price today?

One share of MLNT stock can currently be purchased for approximately $6.25.

How big of a company is Melinta Therapeutics?

Melinta Therapeutics has a market capitalization of $195.27 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 312-767-0291 or via email at [email protected]


MarketBeat Community Rating for Melinta Therapeutics (MLNT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  393 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  658
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Melinta Therapeutics (NASDAQ:MLNT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Melinta Therapeutics in the last 12 months. Their average twelve-month price target is $4.20, suggesting that the stock has a possible downside of 32.80%. The high price target for MLNT is $8.00 and the low price target for MLNT is $2.00. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.432.172.171.92
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.20$3.25$3.25$6.4611
Price Target Upside: 32.80% downside79.37% downside79.37% downside180.92% upside

Melinta Therapeutics (NASDAQ:MLNT) Consensus Price Target History

Price Target History for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ:MLNT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2018WBB SecuritiesUpgradeHold ➝ Buy$8.00HighView Rating Details
5/9/2018Robert W. BairdUpgradeNeutral ➝ OutperformHighView Rating Details
11/30/2017GabelliUpgradeSell ➝ HoldHighView Rating Details
11/30/2017Ladenburg ThalmannUpgradeNeutral ➝ BuyHighView Rating Details
10/26/2017Jefferies GroupReiterated RatingHold ➝ NeutralN/AView Rating Details
8/10/2017Roth CapitalDowngradeBuy ➝ Neutral$8.00 ➝ $4.00HighView Rating Details
8/10/2017Stifel NicolausReiterated RatingHold$4.00HighView Rating Details
1/12/2017JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
1/2/2017CowenReiterated RatingHoldN/AView Rating Details
1/2/2017Cantor FitzgeraldSet Price TargetBuy$28.00N/AView Rating Details
12/30/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
12/30/2016Morgan StanleyUpgradeUnderweight ➝ Equal Weight$5.00 ➝ $5.00N/AView Rating Details
12/29/2016S&P Equity ResearchBoost Price Target$2.65 ➝ $3.15N/AView Rating Details
12/20/2016SunTrust BanksDowngradeBuy ➝ Sell$18.00 ➝ $5.00N/AView Rating Details
11/8/2016Royal Bank of CanadaReiterated RatingBuy$27.50N/AView Rating Details
11/2/2016UBSDowngradeOutperform ➝ Market PerformN/AView Rating Details
11/2/2016Raymond JamesReiterated RatingOutperform ➝ Market PerformN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Melinta Therapeutics (NASDAQ:MLNT) Earnings History and Estimates Chart

Earnings by Quarter for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ:MLNT) Earnings Estimates

Current Year EPS Consensus Estimate: $-4.82 EPS
Next Year EPS Consensus Estimate: $-2.81 EPS

Melinta Therapeutics (NASDAQ MLNT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($1.23)N/AView Earnings Details
3/13/2018Q4 2017($0.59)($1.48)$3.28 million$4.23 millionViewListenView Earnings Details
11/2/2017Q3 2017($1.00)$1.72 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.32)($0.23)$3.58 million$0.86 millionViewListenView Earnings Details
4/28/2017Q1 2017($0.53)($0.37)$3.55 million$4.87 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.57)($0.60)$4.19 million$7.95 millionViewListenView Earnings Details
10/27/2016Q3($0.64)($0.62)$3.90 million$4.00 millionViewListenView Earnings Details
8/1/2016Q2($0.67)($0.51)$3.89 million$3.42 millionViewN/AView Earnings Details
5/1/2016Q1($0.63)($0.61)$3.94 million$2.70 millionViewN/AView Earnings Details
2/24/2016Q4($0.59)($0.48)$3.89 million$5.79 millionViewListenView Earnings Details
10/22/2015Q315($0.52)($0.63)$4.70 million$2.50 millionViewListenView Earnings Details
7/29/2015Q2($0.41)($0.57)$4.60 million$5.05 millionViewListenView Earnings Details
4/30/2015Q1($0.43)($0.41)$2.90 million$13.96 millionViewListenView Earnings Details
2/25/2015Q414($0.46)($0.46)$3.50 million$2.47 millionViewListenView Earnings Details
10/29/2014Q314($0.59)($0.34)$1.59 million$7.77 millionViewN/AView Earnings Details
7/29/2014Q214($0.56)($0.49)$2.56 million$1.90 millionViewN/AView Earnings Details
4/29/2014Q114($0.48)($0.51)$2.10 million$3.10 millionViewN/AView Earnings Details
2/27/2014Q413($0.42)($0.51)$1.25 million$2.07 millionViewN/AView Earnings Details
10/29/2013Q313($0.29)($0.41)$0.46 million$1.20 millionViewN/AView Earnings Details
7/30/2013Q3 2013($0.42)($0.16)$5.13 million$4.60 millionViewN/AView Earnings Details
4/25/2013Q1 2013($1.90)($2.10)ViewN/AView Earnings Details
2/28/2013Q4 2012($1.60)($1.30)ViewN/AView Earnings Details
11/8/2012Q312($0.24)ViewN/AView Earnings Details
8/8/2012Q2 2012($1.05)($2.25)ViewN/AView Earnings Details
5/10/2012Q1 2012($2.15)($1.31)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Melinta Therapeutics (NASDAQ:MLNT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Melinta Therapeutics (NASDAQ MLNT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 27.80%
Institutional Ownership Percentage: 58.65%
Insider Trading History for Melinta Therapeutics (NASDAQ:MLNT)
Institutional Ownership by Quarter for Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics (NASDAQ MLNT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018Vatera Healthcare Partners LlcDirectorBuy5,777,778$13.50$78,000,003.00View SEC Filing  
3/8/2017Dov A Md GoldsteinDirectorSell150,000$3.55$532,500.0095View SEC Filing  
1/13/2017Dov A Md GoldsteinDirectorSell105,460$3.40$358,564.0095View SEC Filing  
1/6/2017Dov A Md GoldsteinDirectorSell937,600$3.41$3,197,216.0095View SEC Filing  
1/3/2017David N GillDirectorBuy5,000$2.94$14,700.005,000View SEC Filing  
3/1/2016David MooreInsiderBuy500$16.18$8,090.001,500View SEC Filing  
1/4/2016Dov A. Md GoldsteinDirectorSell842$30.06$25,310.5250View SEC Filing  
12/15/2015David W. OldachinsiderSell10,000$30.27$302,700.001,100View SEC Filing  
11/9/2015David W. OldachinsiderSell12,200$28.78$351,116.001,100View SEC Filing  
10/26/2015Garheng KongDirectorBuy2,830$17.43$49,326.902,830View SEC Filing  
6/22/2015Dov A Md GoldsteinDirectorSell50,000$35.74$1,787,000.00View SEC Filing  
5/23/2014John JohnsonDirectorBuy10,000$9.10$91,000.00View SEC Filing  
6/19/2013P Sherrill NeffDirectorBuy265,000$7.00$1,855,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Melinta Therapeutics (NASDAQ MLNT) News Headlines

Source:
DateHeadline
Melinta Therapeutics (MLNT) Upgraded by WBB Securities to "Speculative Buy"Melinta Therapeutics (MLNT) Upgraded by WBB Securities to "Speculative Buy"
www.americanbankingnews.com - May 25 at 3:46 PM
Melinta Therapeutics IncMelinta Therapeutics Inc
www.bloomberg.com - May 25 at 8:31 AM
Stock Traders Purchase High Volume of Put Options on Melinta Therapeutics (MLNT)Stock Traders Purchase High Volume of Put Options on Melinta Therapeutics (MLNT)
www.americanbankingnews.com - May 25 at 5:58 AM
US STOCKS ON THE MOVE-Automakers, Recro Pharma, Deere, MedtronicUS STOCKS ON THE MOVE-Automakers, Recro Pharma, Deere, Medtronic
www.nasdaq.com - May 24 at 8:34 AM
BRIEF-Melinta Therapeutics Prices Public Offering Of 22.0 Mln Shares At $5/ShareBRIEF-Melinta Therapeutics Prices Public Offering Of 22.0 Mln Shares At $5/Share
www.reuters.com - May 24 at 8:34 AM
Melinta Therapeutics Announces Pricing of Public Offering of Common StockMelinta Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - May 24 at 8:34 AM
Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare ConferenceMelinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - May 24 at 8:34 AM
Melinta Therapeutics (MLNT) Receives Average Rating of "Hold" from BrokeragesMelinta Therapeutics (MLNT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 24 at 3:46 AM
-$1.29 Earnings Per Share Expected for Melinta Therapeutics (MLNT) This Quarter-$1.29 Earnings Per Share Expected for Melinta Therapeutics (MLNT) This Quarter
www.americanbankingnews.com - May 24 at 1:18 AM
Melinta Therapeutics Announces Proposed Offering of Common StockMelinta Therapeutics Announces Proposed Offering of Common Stock
finance.yahoo.com - May 21 at 5:00 PM
Melinta Therapeutics (MLNT) Upgraded at ValuEngineMelinta Therapeutics (MLNT) Upgraded at ValuEngine
www.americanbankingnews.com - May 15 at 11:34 AM
FY2022 Earnings Estimate for Melinta Therapeutics (MLNT) Issued By GabelliFY2022 Earnings Estimate for Melinta Therapeutics (MLNT) Issued By Gabelli
www.americanbankingnews.com - May 14 at 5:05 AM
Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial ResistanceMelinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance
finance.yahoo.com - May 11 at 8:57 AM
Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance ...Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance ...
globenewswire.com - May 10 at 8:41 AM
Melinta Therapeutics (MLNT) Reports Max $6.2M Award from CARB-X to Advance Clinical Development of ESKAPE Pathogen ProgramMelinta Therapeutics (MLNT) Reports Max $6.2M Award from CARB-X to Advance Clinical Development of ESKAPE Pathogen Program
www.streetinsider.com - May 9 at 5:17 PM
Melinta Therapeutics (MLNT) Stock Rating Upgraded by Robert W. BairdMelinta Therapeutics (MLNT) Stock Rating Upgraded by Robert W. Baird
www.americanbankingnews.com - May 9 at 1:29 PM
Melinta Therapeutics (MLNT) CEO Dan Wechsler on Q1 2018 Results - Earnings Call TranscriptMelinta Therapeutics' (MLNT) CEO Dan Wechsler on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:37 AM
Melinta Therapeutics beats by $0.35, beats on revenueMelinta Therapeutics beats by $0.35, beats on revenue
seekingalpha.com - May 8 at 5:20 PM
Melinta Therapeutics Reports First Quarter 2018 Financial ResultsMelinta Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 5:20 PM
Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual MeetingMelinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting
finance.yahoo.com - May 8 at 8:34 AM
 Analysts Expect Melinta Therapeutics (MLNT) Will Post Quarterly Sales of $13.13 Million Analysts Expect Melinta Therapeutics (MLNT) Will Post Quarterly Sales of $13.13 Million
www.americanbankingnews.com - May 8 at 2:42 AM
Melinta Therapeutics (MLNT) Expected to Announce Earnings of -$1.27 Per ShareMelinta Therapeutics (MLNT) Expected to Announce Earnings of -$1.27 Per Share
www.americanbankingnews.com - May 6 at 3:18 PM
Melinta Therapeutics (MLNT) Receives Average Rating of "Hold" from AnalystsMelinta Therapeutics (MLNT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 29 at 3:24 AM
Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
finance.yahoo.com - April 27 at 5:04 PM
Melinta Therapeutics (MLNT) Announces Updates on Pyrrolocytosine Compound RX-P2382 against ESKAPE PathogensMelinta Therapeutics (MLNT) Announces Updates on Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens
www.streetinsider.com - April 25 at 8:34 AM
Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ...Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ...
globenewswire.com - April 24 at 5:23 PM
Melinta Therapeutics (MLNT) Announces Results from VABOMERE TANGO II TrialMelinta Therapeutics (MLNT) Announces Results from VABOMERE TANGO II Trial
www.streetinsider.com - April 24 at 8:35 AM
Melintas Vabomere shows treatment effect in high-risk patientsMelinta's Vabomere shows treatment effect in high-risk patients
seekingalpha.com - April 23 at 5:02 PM
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in ...Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in ...
globenewswire.com - April 23 at 8:28 AM
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient PopulationsMelinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations
finance.yahoo.com - April 23 at 8:28 AM
$13.13 Million in Sales Expected for Melinta Therapeutics (MLNT) This Quarter$13.13 Million in Sales Expected for Melinta Therapeutics (MLNT) This Quarter
www.americanbankingnews.com - April 21 at 2:54 AM
 Analysts Anticipate Melinta Therapeutics (MLNT) to Post -$1.27 EPS Analysts Anticipate Melinta Therapeutics (MLNT) to Post -$1.27 EPS
www.americanbankingnews.com - April 19 at 3:12 PM
Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial ...Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial ...
globenewswire.com - April 17 at 8:54 AM
Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018
finance.yahoo.com - April 16 at 8:31 AM
Melinta Therapeutics (MLNT) Receives "Hold" Rating from Stifel NicolausMelinta Therapeutics (MLNT) Receives "Hold" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 11 at 3:24 PM
Roth Capital Downgrades Melinta Therapeutics (MLNT) to NeutralRoth Capital Downgrades Melinta Therapeutics (MLNT) to Neutral
www.americanbankingnews.com - April 10 at 10:31 PM
Melinta Therapeutics (MLNT) Downgraded by Zacks Investment Research to SellMelinta Therapeutics (MLNT) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 7 at 3:53 PM
New Compounds Now Available for Antimicrobial Susceptibility Testing: Delafloxacin and Meropenem/VaborbactamNew Compounds Now Available for Antimicrobial Susceptibility Testing: Delafloxacin and Meropenem/Vaborbactam
www.prnewswire.com - April 5 at 5:05 PM
Melinta Therapeutics, Inc. (MLNT) Given Consensus Rating of "Hold" by BrokeragesMelinta Therapeutics, Inc. (MLNT) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 3:26 AM
 Brokerages Anticipate Melinta Therapeutics, Inc. (MLNT) Will Announce Quarterly Sales of $13.13 Million Brokerages Anticipate Melinta Therapeutics, Inc. (MLNT) Will Announce Quarterly Sales of $13.13 Million
www.americanbankingnews.com - April 4 at 2:46 AM
Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement WeatherMelinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather
finance.yahoo.com - April 3 at 8:41 AM
Melinta Therapeutics (MLNT) Upgraded to "Neutral" at Robert W. BairdMelinta Therapeutics (MLNT) Upgraded to "Neutral" at Robert W. Baird
www.americanbankingnews.com - April 2 at 3:15 PM
Melinta Therapeutics (MLNT) Lowered to Sell at Zacks Investment ResearchMelinta Therapeutics (MLNT) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 31 at 4:56 PM
Equities Analysts Offer Predictions for Melinta Therapeutics, Inc.s FY2022 Earnings (MLNT)Equities Analysts Offer Predictions for Melinta Therapeutics, Inc.'s FY2022 Earnings (MLNT)
www.americanbankingnews.com - March 30 at 7:40 AM
Zacks Investment Research Upgrades Melinta Therapeutics (MLNT) to "Hold"Zacks Investment Research Upgrades Melinta Therapeutics (MLNT) to "Hold"
www.americanbankingnews.com - March 17 at 2:08 PM
Melinta Therapeutics (MLNT) CEO Dan Wechsler on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaMelinta Therapeutics' (MLNT) CEO Dan Wechsler on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 15 at 8:34 AM
Melinta Therapeutics (MLNT) Announces  Earnings ResultsMelinta Therapeutics (MLNT) Announces Earnings Results
www.americanbankingnews.com - March 14 at 9:50 AM
Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 14 at 9:00 AM
Melinta Therapeutics to Present at Needham & Companys 17th Annual Healthcare Conference - GlobeNewswire (press release)Melinta Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 14 at 9:00 AM
Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare ConferenceMelinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
finance.yahoo.com - March 14 at 9:00 AM

SEC Filings

Melinta Therapeutics (NASDAQ:MLNT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Melinta Therapeutics (NASDAQ:MLNT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Melinta Therapeutics (NASDAQ MLNT) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.